#### Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

### **Listing of Claims:**

 (Currently Amended) [Claim 1] A furancarbonylguanidine derivative represented by the following of Formula 1 and or pharmaceutically acceptable salts thereof [[.]]

#### [Formula 1]

$$\mathbb{R}^1$$
  $\mathbb{N}$   $\mathbb{N}$ 

### wherein (Wherein;

R¹ and R² are each independently H, F, Cl, Br, I, CF<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>, NO<sub>2</sub>, NH<sub>2</sub>, C<sub>1</sub>~C<sub>5</sub> straight or branched alkyl, or OR<sup>a</sup>; and [[. And,]]

Ra is H, CF3, C1~C5 straight or branched alkyl, or phenyl. [[)]]

- (Currently Amended) [Claim 2] The furancarbonylguanidne derivative and or
  pharmaceutically acceptable salts thereof as set forth in claim 1, wherein the compound of
  Formula 1 comprises:
  - 1) [5- (2-fluorophenyl) furan-2-ylcarbonyl] guanidine,
  - 2) [5- (3-fluorophenyl) furan-2-ylcarbonyl] guanidine,
  - 3) [5- (4-fluorophenyl) furan-2-ylcarbonyl] guanidine,
  - 4) [5-phenylfuran-2-ylcarbonyl] guanidine,
  - 5) [5-(2-chlorophenyl) furan-2-ylcarbonyl] guanidine,
  - 6) [5- (3-chlorophenyl) furan-2-ylcarbonyl] guanidine,
  - 7) [5- (4-chlorophenyl) furan-2-ylcarbonyl] guanidine,
  - 8) [5- (2-methylphenyl) furan-2-ylcarbonyl] guanidine,
  - 9) [5- (3-methylphenyl) furan-2-ylcarbonyl] guanidine,
  - 10) [5- (4-methylphenyl) furan-2-ylcarbonyl] guanidine,

- 11) [5- [2- (trifluoromethyl) phenyl] furan-2-ylcarbonyl] guanidine,
- 12) [5- [3- (trifluoromethyl) phenyl] furan-2-ylcarbonyl] guanidine,
- 13) [5- [4- (trifluoromethyl) phenyl] furan-2-ylcarbonyl] guanidine,
- 14) [5- (2-methoxyphenyl) furan-2-ylcarbonyl] guanidine,
- 15) [5- (3-methoxyphenyl) furan-2-ylcarbonyl] guanidine,
- 16) [5- (4-methoxyphenyl) furan-2-ylcarbonyl] guanidine,
- 17) [5- (2-nitrophenyl) furan-2-ylcarbonyl] guanidine,
- [5- (3-nitrophenyl) furan-2-ylcarbonyl] guanidine,
- 19) [5- (4-nitrophenyl) furan-2-ylcarbonyl] guanidine,
- 20) [5- (2-aminophenyl) furan-2-ylcarbonyl] guanidine,
- 21) [5- (3-aminophenyl) furan-2-ylcarbonyl] guanidine,
- 22) [5- (4-aminophenyl) furan-2-ylcarbonyl] guanidine,
- 23) [5- (2-ethylphenyl) furan-2-ylcarbonyl] guanidine,
- 24) [5- (2-ethoxyphenyl) furan-2-ylcarbonyl] guanidine,
- 25) [5- (2-isoproxyphenyl)furan-2-ylcarbonyl]guanidine,
- 25) [5- (2-isopioxyphenyi)tatan 2 yioatoonyi]Baamasso,
- [5- (2-phenoxyphenyl) furan-2-ylcarbonyl] guanidine,
- [5- (2, 6-dfluorophenyl) furan-2-ylcarbonyl] guanidine,
- 28) [5- (3, 5-dfluorophenyl) furan-2-ylcarbonyl] guanidine,
- 29) [5- (2, 4-dfluorophenyl) furan-2-ylcarbonyl] guanidine,
- 30) [5- (2, 5-dfluorophenyl) furan-2-ylcarbonyl] guanidine,
- 31) [5- (2, 3-dfluorophenyl) furan-2-ylcarbonyl] guanidine,
- 32) [5- (2-chloro-6-fluorophenyl) furan-2-ylcarbonyl] guanidine,
- 33) [5- (2-fluoro-5-methylphenyl) furan-2-ylcarbonyl] guanidine,
- 34) [5- (2-methyl-5-fluorophenyl) furan-2-ylcarbonyl] guanidine,
- 35) [5- (2-methoxy-5-fluorophenyl) furan-2-ylcarbonyl] guanidine,
- 36) [5- (3, 5-dichlorophenyl) furan-2-ylcarbonyl] guanidine,
- 37) [5- (2, 3-dichlorophenyl) furan-2-ylcarbonyl] guanidine,
- 38) [5- (2, 5-dichlorophenyl) furan-2-ylcarbonyl] guanidine,
- 39) [5- (2-methoxy-5-chlorophenyl) furan-2-ylcarbonyl] guanidine,
- 40) [5- (2-chloro-5-trifluoromethylphenyl) furan-2-ylcarbonyl] guanidine,
- 41) [5- (2, 6-dimethylphenyl) furan-2-ylcarbonyl] guanidine,

42) [5- (3, 5-dimethylphenyl) furan-2-ylcarbonyl] guanidine,

43) [5- (2, 5-dimethylphenyl) furan-2-ylcarbonyl] guanidine,

44) [5- (2, 3-dimethylphenyl) furan-2-ylcarbonyl] guanidine,

45) [5- (2, 6-dimethoxyphenyl) furan-2-ylcarbonyl] guanidine,

46) [5- (2, 3-dimethoxyphenyl) furan-2-ylcarbonyl] guanidine,

47) [5- (2, 5-dimethoxyphenyl) furan-2-ylcarbonyl] guanidine,

48) [5- (2-methoxy-5-bromophenyl) furan-2-ylcarbonyl] guanidine,

49) [5- (2-hydroxy-5-chlorophenyl) furan-2-ylcarbonyl] guanidine,

50) [5- (2-ethoxy-5-chlorophenyl) furan-2-ylcarbonyl] guanidine, and

51) [5- (2-isopropoxy-5-chlorophenyl) furan-2-ylcarbonyl] guanidine.

# 3. (Currently Amended) [Claim 3] A preparation method for preparing a

furancarbonylguanidine compound of Formula 1, as shown in the below Scheme 1, comprising:

reacting in which a carboxylic acid derivative of compound of Formula II is reacted with

guanidine in the presence of base or with an excess amount of guanidine [[.]]

# [Scheme 1]

$$\mathbb{R}^{1} \xrightarrow{\text{guanidine}} \mathbb{R}^{1} \xrightarrow{\text{NH}_{2}} \mathbb{N} \xrightarrow{\text{NH}_{2}} \mathbb{N} = \mathbb{N} \times \mathbb{N}$$

wherein (Wherein,

R1 and R2 are as defined in Formula 1, and each independently H, F, Cl, Br, I, CF3.

SO<sub>2</sub>CH<sub>3</sub>, NO<sub>2</sub>, NH<sub>2</sub>, C<sub>1</sub>~C<sub>5</sub> straight or branched alkyl, or OR<sup>a</sup>;

Ra is H, CF3, C1~C5 straight or branched alkyl, or phenyl; and

L is a leaving group that is easily left by guanidine. [[)]]

4. (Currently Amended) [Claim 4] A preparation method for preparing a furancarbonylguanidine compound of Formula 1, as shown in the below Scheme 2, comprising:

reacting in which a carboxylic acid of compound of Formula III is reacted with guanidine in the presence of a condensating condensation agent [[.]]

wherein (Wherein,

R<sup>1</sup> and R<sup>2</sup> are as defined in Formula 1.) cach independently H, F, Cl, Br, I, CF<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>, NO<sub>2</sub>, NH<sub>2</sub>, C<sub>1</sub>-C<sub>5</sub> straight or branched alkyl, or OR<sup>3</sup>; and

Ra is H, CF3, C1~C5 straight or branched alkyl, or phenyl.

(Currently Amended) [Claim-5] The preparation method as set forth in claim 4, wherein
the eendensating condensation agent is selected from a the group consisting of
N, N-carbonyldiimidazole, dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIPC),
1-ethyl-3- (3-dimethylaminopropyl) carbodiimide (WSC) and diphenylphosphonylazide (DPPA).

 (Currently Amended) [Claim 6] A preparation method for preparing a furan compound having a benzene ring at the 5<sup>th</sup> site, as shown in the below Scheme 3a, comprising:

reacting in which a phenylboronic acid or stanylphenyl derivative compound of Formula IV and with a 5-halofuran compound of Formula V are reacted in the presence of a palladium catalyst, which is a Stille-type coupling or Suzuki-type coupling, to give form a compound of Formula II<sub>1</sub> [[.]]

## [Scheme 3a]

$$R^{1}$$
 $X + Y O CH_{3}$ 
 $CCH_{3}$ 
 $R^{2}$ 
 $(IV)$ 
 $(V)$ 
 $(V)$ 
 $(II_{1})$ 

$$\begin{array}{c|c} R_2 & + & & & \\ \hline \\ R_2 & & & \\ \hline \\ (M) & (V) & \\ \end{array}$$

wherein (Wherein,

R<sup>1</sup> and R<sup>2</sup> are as defined in Formula 1, in which each independently H, F, Cl, Br, L, CF<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>, NO<sub>2</sub>, NH<sub>2</sub>, C<sub>1</sub>~C<sub>5</sub> straight or branched alkyl, or OR<sup>a</sup>;

Ra is H, CF3, C1~C5 straight or branched alkyl, or phenyl;

X is B(OH)2, BCl2, BBr2, SnBu3, SnMe3, or ZnCl, and

Y is a halogen (Br, I, Cl) or OSO<sub>2</sub>CF<sub>3</sub> wherein the halogen is Br, I or Cl. [[)]]

 (Currently Amended) [Claim-7] A pharmaceutical composition containing furancarbonylguanidine derivative and or pharmaceutically acceptable salts thereof of claim 1-as an elective ingredient for the prevention and the treatment of isohemic heart disease.

### 8-10. (Cancelled)